Overview
Multidrug dataset contains the expression of 48 known human ABC transporters with patterns of drug activity in 60 diverse cancer cell lines (the NCI-60) used by the National Cancer Institute to screen for anticancer activity. The data come from a pharmacogenomic study (Szakács et al., 2004) in which two kinds of measurements acquired on the NCI-60 cancer cell lines are considered:
- the expression of the 48 human ABC transporters measured by real-time quantitative RT-PCR for each cell line;
- the activity of 1429 drugs expressed as GI50 which corresponds to the concentration at which the drug induces 50% inhibition of cellular growth for the tested cell line.
The NCI-60 panel includes cell lines derived from cancers of colorectal (7 cell lines), renal (8), ovarian (6), breast (8), prostate (2), lung (9) and central nervous system origin (6), as well as leukemias (6) and melanomas (8). It was set up by the Developmental Therapeutics Program of the National Cancer Institute (NCI, one of the U.S. National Institutes of Health) to screen the toxicity of chemical compound repositories. The expressions of the 48 human ABC transporters is available as a supplement to the paper of Szakács et al.(2004).
The drug dataset consist of 118 compounds whose mechanisms of action are putatively classifiable (Weinsteinet al., 1992) and a larger set of 1400 compounds that have been tested multiple times and whose screening data met quality control criteria described elsewhere (Scherf et al., 2000). The two were combined to form a joint dataset that included 1429 compounds.